Dashboard
Manage Tickers

SMMT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

summit-therapeutics-to-present-phase-iii-lung-cancer-trial-results-for-ivonescimab-at-sitc-2025
Summit Therapeutics To Present Phase III L...
10/31/2025 11:04:19

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that results ...

alpha-buying-when-insiders-buy-big--why-it-works-in-every-market
Alpha Buying: When Insiders Buy Big & Why ...
10/30/2025 14:57:45

summit-therapeutics-files-for-shelf-of-up-to-267m-shares-of-common-stock-by-selling-stockholders
Summit Therapeutics Files For Shelf Of Up ...
10/29/2025 21:19:27

-SEC Filing

guggenheim-reiterates-buy-on-summit-therapeutics-maintains-40-price-target
Guggenheim Reiterates Buy on Summit Therap...
10/22/2025 13:14:27

Guggenheim analyst Brad Canino reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.

summit-therapeutics-accepts-offers-from-investors-to-purchase-2668m-shares-at-1874share-raising-500m-in-proceeds
Summit Therapeutics Accepts Offers From In...
10/22/2025 12:04:51

barclays-maintains-underweight-on-summit-therapeutics-raises-price-target-to-16
Barclays Maintains Underweight on Summit T...
10/21/2025 12:50:08

Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Underweight and raises the price target fro...

hc-wainwright--co-maintains-buy-on-summit-therapeutics-lowers-price-target-to-40
HC Wainwright & Co. Maintains Buy on Summi...
10/21/2025 11:08:08

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the pri...

citigroup-maintains-buy-on-summit-therapeutics-raises-price-target-to-40
Citigroup Maintains Buy on Summit Therapeu...
10/20/2025 15:33:35

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...

whats-going-on-with-summit-therapeutics-stock-on-monday
What's Going On With Summit Therapeutics S...
10/20/2025 14:05:00

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late...

jmp-securities-reiterates-market-outperform-on-summit-therapeutics-maintains-40-price-target
JMP Securities Reiterates Market Outperfor...
10/20/2025 13:39:02

JMP Securities analyst Reni J. Benjamin reiterates Summit Therapeutics (NASDAQ:SMMT) with a Market Outperform and maintains ...

retail-investors-top-stocks-with-earnings-this-week-tesla-netflix-intel-and-more
Retail Investors' Top Stocks With Earnings...
10/20/2025 11:53:01

Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.

summit-therapeutics-q3-adj-eps-013-inline
Summit Therapeutics Q3 Adj. EPS $(0.13), I...
10/20/2025 10:52:59

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This...

summit-therapeutics-said-that-based-on-harmoni-trial-data-it-plans-to-submit-a-biologics-license-application-for-ivonescimab-plus-chemotherapy-for-epidermal-growth-factor-receptor-mutant-non-small-cell-lung-cancer-in-q4-of-2025
Summit Therapeutics Said That Based On HAR...
10/20/2025 10:48:28

Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study ResultsExpansion of Summit'...

Core News & Articles
Earnings Scheduled For October 20, 2025
10/20/2025 08:32:45

reported-sunday-summit-announces-ivonescimab-achieved-median-progression-free-survival-of-1114-months-compared-to-690-months-for-tislelizumab-plus-chemotherapy-in-landmark-harmoni-6-trial
Reported Sunday, Summit Announces Ivonesci...
10/20/2025 07:16:07

Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti...

an-overview-of-summit-therapeuticss-earnings
An Overview of Summit Therapeutics's Earnings
10/17/2025 14:01:21

summit-therapeutics-initiates-global-phase-iii-harmoni-gi3-trial-evaluating-ivonescimab-plus-chemotherapy-in-metastatic-colorectal-cancer
Summit Therapeutics Initiates Global Phase...
10/17/2025 11:04:42

HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLCClinical Trial Site Activati...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/08/2025 17:35:32

alpha-buying-the-3-stocks-that-just-got-this-1-million-vote-of-confidence
Alpha Buying: The 3 Stocks That Just Got T...
10/01/2025 18:39:50

intel-marvell-electronic-arts-are-among-the-top-10-large-cap-gainers-last-week-sep-22---sep-26-are-the-others-in-your-portfolio
Intel, Marvell, Electronic Arts Are Among ...
09/28/2025 13:25:51

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION